Sun's China, Japan Plans Gather Pace
Upbeat On IL-23 Prospects In US, Ilumya Faring ‘Reasonably’
Sun expects interleukin-23-targeting drugs to stay a preferred treatment option for psoriasis in the US and saw some sales uptick for its Ilumya in that market in Q2, although it isn’t keen on an auto injector option. Management was also upbeat on prospects in China and Japan.
